NEXALIS THERAPEUTICS LTD — Director's Dealing 2017

Nov 6, 2017

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity: Lifespot Health Limited ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Mandel
Date of appointment	31 October 2017

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature ofinterestNote: Provide details of the circumstancesgiving rise to the relevant interest. Nil	Number & class of Securities Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Non-Executive Director Agreement
Nature of interest	Agreement to issue unlisted options
Name of registered holder(if issued securities)	Tobeissued,subjecttoshareholderapproval, to David Mandel or his nominee.
No. and class of securities towhich interest relates	Subject to shareholder approval, agreementto issue 500,000 options exercisable at $0.20each expiring 1 November 2020 and 500,000options exercisable at $0.30 each expiring 1November 2020.

See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002